Petmed Express PETS

NASDAQ PETS

$1.71 -0.05 (-2.84%)

At close: Sep 9, 2026 · 4:00 PM EDT

Key Stats

Market Cap37.08 Mn

P/E-1.27

P/S0.22

Div. Yield0.00

Revenue Growth (1y) (Qtr)-19.86

Add ratio to table…

About

PetMed Express, Inc. is a nationwide direct to consumer pet health and wellness retailer. The company markets and sells prescription medications, generic medications, compounded prescriptions, pharmacy fulfillment services and autoship options through its websites Petmeds.com and PetCareRx.com, its toll free customer contact center 1800PetMeds and its iOS and Android mobile applications. It also offers non prescription health and wellness products, prescription and non prescription pet foods, treats and a range of over the counter items such as vitamins, supplements and hygiene supplies. PetMed Express, Inc. connects with licensed veterinarians to verify prescriptions before shipment and provides educational content through its pethealthmd.com portal. The company serves pet owners across all fifty states and has built relationships with more than seventy five thousand veterinarians.

PetMed Express, Inc. generates revenue primarily from the sale of prescription medications, generic medications, compounded prescriptions, over the counter products, pet foods and treats through its ecommerce platforms and customer contact center. The company also earns income from autoship subscription programs, telehealth consultations, pet insurance offerings and employee benefit partnerships. Revenue is derived from retail sales to individual pet owners across the United States.

PetMed Express, Inc. holds a notable position in the pet health retail sector as a direct to consumer online pharmacy with a broad product assortment. The company faces competition from veterinarians, local and national chain specialty retailers, vendors own ecommerce sites and several large retailers that have entered the pet pharmacy space. Its competitive advantage stems from nearly three decades of industry experience, a team of qualified pharmacists and technicians trained in veterinary pharmacology and licensed in all fifty states, a rigorous five point verification process that meets FDA and DEA standards, and accreditation from the National Association of Boards of Pharmacy and LegitScript. Additionally, the company benefits from a dedicated customer care team that shares a passion for pets and a long standing network of more than seventy five thousand veterinarian relationships.

PetMed Express, Inc. serves individual pet owners across the United States, with a substantial portion of its customer base located in California, Florida, Texas, New York, Pennsylvania, North Carolina, Georgia and Virginia. The company reports that more than 1.7 million customers have made a purchase within the last three fiscal years, including those acquired through the PetCareRx transaction. It attracted approximately 351,000 new customers in fiscal 2025 and 457,000 new customers in fiscal 2024. The average order value was about ninety seven dollars in fiscal 2025 and ninety four dollars in fiscal 2024. In addition to retail consumers, the company reaches employers through its PetAssure broker network which offers pet health benefits as part of workplace wellness programs.

Investment Thesis

▲ Bull case

PetMed Express is establishing a sustainable foundation for long-term growth through operational and technological modernization, particularly in its pharmacy and fulfillment capabilities. The successful implementation of a new ERP system, fraud prevention system, and call center technology has modernized the company’s tech stack, reducing operational risk and improving customer experience. These investments, while costly in the short term, are now complete and position the company to scale efficiently without proportional increases in overhead. As Leslie Campbell noted, these initiatives serve as the backbone of phone and order management systems, directly supporting improvements in prescription medication sales and auto ship sign-ups—two high-margin, recurring revenue streams. The sequential quarterly increase in Q4 net sales, the first since fiscal year 2024, demonstrates that these operational improvements are beginning to translate into top-line momentum. Furthermore, the company’s renewed focus on customer retention, enabled by better technology and service reliability, could stabilize and eventually grow its core subscription-based auto ship model, which historically has higher lifetime value and lower customer acquisition costs. With cost structure now lower and more aligned with business size, as stated by Campbell, any future revenue growth will flow more directly to profitability, creating operating leverage that the market may be underestimating given the recent history of losses.
PetMed Express is leveraging its deep pharmacy expertise and tenured workforce to expand into high-potential B2B channels, creating a new avenue for revenue diversification beyond direct-to-consumer sales. The recently announced master services agreement with Rural King represents a strategic pivot toward white-label pharmacy fulfillment services, allowing the company to monetize its infrastructure and regulatory compliance capabilities by serving third-party retailers. This initiative taps into the growing trend of omnichannel pet care distribution, where brick-and-mortar retailers seek reliable partners to offer prescription medications and health products under their own brands. Unlike the unsuccessful wholesale inventory initiative referenced in Q3—which was a departure from core competencies—this B2B model aligns closely with PetMed’s strengths in pharmaceutical handling, e-prescribing, and fulfillment logistics. Management highlighted this as a key part of their strategy to expand market footprint, noting that such offerings represent a significant opportunity to leverage their expertise. Given the company’s 30-year history, regulatory compliance reinstatement, and long-tenured employee base (with over 40 employees having more than a decade of service and half nearing 20 years), PetMed possesses unique intellectual and operational capital that is difficult for new entrants to replicate. The market may be overlooking this shift as a potential multi-year growth driver, especially if similar partnerships are signed with other regional or national retailers.
PetMed Express’s financial restructuring and cost optimization efforts are creating a path to profitability that is not fully reflected in current valuations, particularly as non-recurring burdens roll off. The company exited underperforming vendor relationships in the second half of fiscal year 2026, yielding approximately $6.1 million in annualized savings—equivalent to roughly 3.4% of fiscal year 2026 sales—and successfully settled its New York State sales tax liability, which reduced net loss by $2.8 million in Q4 alone. These actions, combined with a lower and more aligned cost structure, mean that the base level of operating expenses is now significantly cleaner than in prior years. Furthermore, the $26.7 million goodwill impairment and $2.1 million inventory write-down are one-time, non-cash charges that do not reflect ongoing operational performance. Adjusted EBITDA, while still negative at $15.4 million for the full year, showed improvement in the second half, and the sequential Q4 sales increase suggests the revenue decline is moderating. With no debt and $21.4 million in cash as of March 31, 2026, the company has a strong liquidity position to weather near-term volatility while executing its strategic initiatives. The market may be penalizing the stock for historical losses without fully crediting the run-rate improvement in core operations or the potential for profitability once revenue stabilizes at current levels, especially given the 270 basis point gross margin improvement in Q4 driven by the tax settlement and operational discipline.

PetMed Express is establishing a sustainable foundation for long-term growth through operational and technological modernization, particularly in its pharmacy and fulfillment capabilities. The successful implementation of a new ERP system, fraud prevention system, and call center technology has modernized the company’s tech stack, reducing operational risk and improving customer experience. These investments, while costly in the short term, are now complete and position the company to scale efficiently without proportional increases in overhead. As Leslie Campbell noted, these initiatives serve as the backbone of phone and order management systems, directly supporting improvements in prescription medication sales and auto ship sign-ups—two high-margin, recurring revenue streams. The sequential quarterly increase in Q4 net sales, the first since fiscal year 2024, demonstrates that these operational improvements are beginning to translate into top-line momentum. Furthermore, the company’s renewed focus on customer retention, enabled by better technology and service reliability, could stabilize and eventually grow its core subscription-based auto ship model, which historically has higher lifetime value and lower customer acquisition costs. With cost structure now lower and more aligned with business size, as stated by Campbell, any future revenue growth will flow more directly to profitability, creating operating leverage that the market may be underestimating given the recent history of losses.
PetMed Express is leveraging its deep pharmacy expertise and tenured workforce to expand into high-potential B2B channels, creating a new avenue for revenue diversification beyond direct-to-consumer sales. The recently announced master services agreement with Rural King represents a strategic pivot toward white-label pharmacy fulfillment services, allowing the company to monetize its infrastructure and regulatory compliance capabilities by serving third-party retailers. This initiative taps into the growing trend of omnichannel pet care distribution, where brick-and-mortar retailers seek reliable partners to offer prescription medications and health products under their own brands. Unlike the unsuccessful wholesale inventory initiative referenced in Q3—which was a departure from core competencies—this B2B model aligns closely with PetMed’s strengths in pharmaceutical handling, e-prescribing, and fulfillment logistics. Management highlighted this as a key part of their strategy to expand market footprint, noting that such offerings represent a significant opportunity to leverage their expertise. Given the company’s 30-year history, regulatory compliance reinstatement, and long-tenured employee base (with over 40 employees having more than a decade of service and half nearing 20 years), PetMed possesses unique intellectual and operational capital that is difficult for new entrants to replicate. The market may be overlooking this shift as a potential multi-year growth driver, especially if similar partnerships are signed with other regional or national retailers.
PetMed Express’s financial restructuring and cost optimization efforts are creating a path to profitability that is not fully reflected in current valuations, particularly as non-recurring burdens roll off. The company exited underperforming vendor relationships in the second half of fiscal year 2026, yielding approximately $6.1 million in annualized savings—equivalent to roughly 3.4% of fiscal year 2026 sales—and successfully settled its New York State sales tax liability, which reduced net loss by $2.8 million in Q4 alone. These actions, combined with a lower and more aligned cost structure, mean that the base level of operating expenses is now significantly cleaner than in prior years. Furthermore, the $26.7 million goodwill impairment and $2.1 million inventory write-down are one-time, non-cash charges that do not reflect ongoing operational performance. Adjusted EBITDA, while still negative at $15.4 million for the full year, showed improvement in the second half, and the sequential Q4 sales increase suggests the revenue decline is moderating. With no debt and $21.4 million in cash as of March 31, 2026, the company has a strong liquidity position to weather near-term volatility while executing its strategic initiatives. The market may be penalizing the stock for historical losses without fully crediting the run-rate improvement in core operations or the potential for profitability once revenue stabilizes at current levels, especially given the 270 basis point gross margin improvement in Q4 driven by the tax settlement and operational discipline.

▼ Bear case

PetMed Express continues to face structural challenges in its core prescription medication business, which remains the primary driver of its prolonged revenue decline despite management’s optimistic commentary. Net sales for fiscal year 2026 declined 21.1% year-over-year, with prescription medication sales specifically cited by both Leslie Campbell and Doug Krulik as the main factor behind the drop in both Q4 and full-year results. Although Q4 showed a sequential improvement and a slowing of the year-over-year decline, the underlying trend remains negative, and the company offered no clear explanation for why prescription sales are falling—whether due to increased competition from larger retailers like Chewy and Amazon, shifting veterinarian prescribing habits, or customer attrition to alternative channels. The reliance on auto ship sign-ups as a green shoot is insufficient to offset broad-based declines, especially given that auto ship growth alone cannot compensate for losses in one-time or non-recurring prescription orders. Furthermore, the company’s gross margin improvement in Q4 was largely attributable to the one-time benefit of the New York sales tax settlement, not sustainable operational efficiency, suggesting that the underlying profitability of the core business may still be weak. Without a credible, differentiated strategy to regain market share in prescription fulfillment—a category increasingly dominated by scale players—the company risks continued erosion of its foundational revenue stream.
PetMed Express’s pivot to B2B and white-label services, while promising in theory, remains unproven at scale and may not generate sufficient revenue to offset ongoing declines in its direct-to-consumer business in the near term. The master services agreement with Rural King was announced with Rural King is a positive step, but management provided no details on the expected revenue contribution, timeline for ramp-up, or margin profile of this partnership. Given the company’s history of unsuccessful departures from its core business—such as the wholesale inventory initiative that led to a $2.1 million write-down in Q3—there is justified skepticism about whether this new B2B strategy will succeed where past diversification attempts failed. The lack of transparency around customer acquisition costs, implementation timelines, and potential channel conflict with existing direct-to-consumer operations raises concerns about execution risk. Moreover, entering the B2B space requires competing against established players with deeper relationships in retail distribution and potentially lower cost structures due to scale. Without clear metrics or milestones shared during the earnings call, the market may be justified in viewing this as a speculative long-term option rather than a near-term catalyst, especially given the company’s constrained financial resources and need to prioritize core stabilization.
PetMed Express’s financial recovery remains fragile and highly dependent on one-time improvements, with lingering risks from past governance and compliance issues that could resurface or constrain future flexibility. Although the company has remediated three previously disclosed internal control weaknesses and regained regulatory compliance, the fact that it required a whistleblower investigation, executive severance, and $4.5 million in nonrecurring legal and professional costs in fiscal year 2026 suggests deeper cultural or systemic issues may persist. The company’s ability to maintain compliance and avoid future regulatory scrutiny is not guaranteed, particularly in the highly regulated pet pharmacy space, where errors in dispensing, labeling, or state-specific tax compliance can lead to penalties, reputational damage, or loss of licensure. Furthermore, while the company currently has no debt and $21.4 million in cash, its quarterly cash burn remains significant—Adjusted EBITDA was negative $15.4 million for the full year—and without a clear path to positive EBITDA in the near term, it may need to rely on fundraising or asset sales to sustain operations. The market may be underestimating the execution risk involved in turning around a business with declining sales, ongoing investments in technology and partnerships, and a need to rebuild trust with both customers and regulators, all while operating in a highly competitive and consolidating industry.

PetMed Express continues to face structural challenges in its core prescription medication business, which remains the primary driver of its prolonged revenue decline despite management’s optimistic commentary. Net sales for fiscal year 2026 declined 21.1% year-over-year, with prescription medication sales specifically cited by both Leslie Campbell and Doug Krulik as the main factor behind the drop in both Q4 and full-year results. Although Q4 showed a sequential improvement and a slowing of the year-over-year decline, the underlying trend remains negative, and the company offered no clear explanation for why prescription sales are falling—whether due to increased competition from larger retailers like Chewy and Amazon, shifting veterinarian prescribing habits, or customer attrition to alternative channels. The reliance on auto ship sign-ups as a green shoot is insufficient to offset broad-based declines, especially given that auto ship growth alone cannot compensate for losses in one-time or non-recurring prescription orders. Furthermore, the company’s gross margin improvement in Q4 was largely attributable to the one-time benefit of the New York sales tax settlement, not sustainable operational efficiency, suggesting that the underlying profitability of the core business may still be weak. Without a credible, differentiated strategy to regain market share in prescription fulfillment—a category increasingly dominated by scale players—the company risks continued erosion of its foundational revenue stream.
PetMed Express’s pivot to B2B and white-label services, while promising in theory, remains unproven at scale and may not generate sufficient revenue to offset ongoing declines in its direct-to-consumer business in the near term. The master services agreement with Rural King was announced with Rural King is a positive step, but management provided no details on the expected revenue contribution, timeline for ramp-up, or margin profile of this partnership. Given the company’s history of unsuccessful departures from its core business—such as the wholesale inventory initiative that led to a $2.1 million write-down in Q3—there is justified skepticism about whether this new B2B strategy will succeed where past diversification attempts failed. The lack of transparency around customer acquisition costs, implementation timelines, and potential channel conflict with existing direct-to-consumer operations raises concerns about execution risk. Moreover, entering the B2B space requires competing against established players with deeper relationships in retail distribution and potentially lower cost structures due to scale. Without clear metrics or milestones shared during the earnings call, the market may be justified in viewing this as a speculative long-term option rather than a near-term catalyst, especially given the company’s constrained financial resources and need to prioritize core stabilization.
PetMed Express’s financial recovery remains fragile and highly dependent on one-time improvements, with lingering risks from past governance and compliance issues that could resurface or constrain future flexibility. Although the company has remediated three previously disclosed internal control weaknesses and regained regulatory compliance, the fact that it required a whistleblower investigation, executive severance, and $4.5 million in nonrecurring legal and professional costs in fiscal year 2026 suggests deeper cultural or systemic issues may persist. The company’s ability to maintain compliance and avoid future regulatory scrutiny is not guaranteed, particularly in the highly regulated pet pharmacy space, where errors in dispensing, labeling, or state-specific tax compliance can lead to penalties, reputational damage, or loss of licensure. Furthermore, while the company currently has no debt and $21.4 million in cash, its quarterly cash burn remains significant—Adjusted EBITDA was negative $15.4 million for the full year—and without a clear path to positive EBITDA in the near term, it may need to rely on fundraising or asset sales to sustain operations. The market may be underestimating the execution risk involved in turning around a business with declining sales, ongoing investments in technology and partnerships, and a need to rebuild trust with both customers and regulators, all while operating in a highly competitive and consolidating industry.

Segments Breakdown of Revenue (2026)

Peer group

Peer Comparison

Companies in the Pharmacies

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	PETS	Petmed Express Inc	primary	0.04 Bn	-1.27	0.22	-
2	BSAC	Banco Santander Chile	secondary	950.85 Bn	-0.68	-	652.30 Bn
3	WMT	Walmart Inc.	secondary	841.10 Bn	37.38	1.14	57.42 Bn
4	COST	Costco Wholesale Corp /New	secondary	400.57 Bn	45.32	1.36	5.67 Bn
5	PG	PROCTER & GAMBLE Co	secondary	332.67 Bn	20.61	3.82	34.14 Bn
6	PEP	Pepsico Inc	secondary	186.88 Bn	22.64	1.93	63.82 Bn
7	ABT	Abbott Laboratories	secondary	183.04 Bn	33.74	3.93	32.61 Bn
8	CVS	CVS HEALTH Corp	secondary	122.38 Bn	25.05	0.29	61.41 Bn

Petmed Express PETS

About

Investment Thesis

Segments Breakdown of Revenue (2026)

Peer Comparison

Create an account

Sign In

Reset Password